Efficacy Evaluation of Treatment for Children with Refractory Renal Tumor

Xiangdong Tian,Jie Yan,Yanna Cao,Zhongyuan Li,Yao Tian,Qiang Zhao
2017-01-01
Abstract:Background and Objectives: The treatment for refractory renal tumor is still not satisfactory. The authors analyzed retrospectively their experience in the treatment of refractory renal tumor diagnosed from 2009 to 2014. Methods: A retrospective study of 28 patients with refractory renal tumor confirmed by pathology was analyzed in our center. The clinical characteristics of patients were illustrated and the efficacy of two different chemotherapy regimens was compared. Results: Among the 28 patients suffered with refractory renal tumor, 17 patients survived out of 28 patients. Eleven patients died, and nine of them died of disease relapse or progression. Pathology, extent of surgery and chemotherapy regimen were closely associated with 3-year overall survival (OS) and 3-year progression-free survival (PFS). In addition, pathology type and chemotherapy regimen had further impact on prognosis. The 3-year overall survival (OS) rate was 84.4% for patients with UH-1 regimen and 48.6% for patients with WT-2009 regimen, respectively (P=0.026). The 3-year progression-free survival (PFS) was 67% and 45%, respectively (P=0.048). The3-year survival rate appeared to be better in the UH-1 group than that in the WT-2009 group. Conclusion: Refractory renal tumor treatment outcome is reasonable but still needs further improvement. Selection of UH-1 regimen effectively improves the survival rate, though longer follow-up observation for safety is still needed.
What problem does this paper attempt to address?